risks of glp 1 agonists The promise and peril GLP-1 agonists: What we do (and don't) know as of August 2024 The GLP-1 Agonists and Obesity:

Diabetes Obes Metab (2016) 18(3):20316

CA, congenital anomaly

Due to their diverse structures, the pharmacokinetic profiles vary, and a prolonged half-life may be associated with an increased risk of adverse events

These clocks detect DNA methylation, chemical marks on DNA that help regulate how genes are turned on or off without changing the genetic sequence itself

Researchers who want to examine the granular differences between these compounds can start with the retatrutide versus semaglutide detailed breakdown and the semaglutide versus tirzepatide head-to-head comparison for the complete picture

Genome-wide linkage and association study identifies novel genes and pathways implicated in polycystic ovarian syndrome